In addition, the higher circulating FFAs with KrO may result in a higher influx of fat to the liver, thereby counteracting the beneficial effects on hepatic fat oxidation (i.e., PPARA, ACOX1, PPARGC1A), altogether leading to comparable hepatic steatosis as in the HFD controls. Here, PPARGC1A is linked to fatty liver disease.